PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



Q&A GenoSpace's John Quackenbush .pdf



Original filename: Q&A_ GenoSpace's John Quackenbush.pdf

This PDF 1.4 document has been generated by , and has been sent on pdf-archive.com on 29/01/2015 at 15:52, from IP address 75.149.x.x. The current document download page has been viewed 413 times.
File size: 203 KB (4 pages).
Privacy: public file




Download original PDF file









Document preview


1/29/2015

Q&A: GenoSpace's John Quackenbush on Making Data Accessible for Research, Clinical, and Patient Use | GenomeWeb

Q&A: GenoSpace's John Quackenbush on Making
Data Accessible for Research, Clinical, and
Patient Use
Jun 21, 2013

Premium
John Quackenbush, the founder and CEO of GenoSpace, a Cambridge, Mass.based bioinformatics company, was one of 13 individuals recognized by the
White House's Office of Science and Technology Policy as an Open Science
Champion of Change — a program that honors efforts to promote and use open
scientific data and publications.
His firm was recognized for its efforts to create tools that make clinical and
genomic data available for biomedical research and personalized medicine as
well as for the work it's currently doing with the Multiple Myeloma Research
Foundation, a non-profit organization that focused on research and the
development of better treatments for multiple myeloma. Kathy Guisti, MMRF's founder and CEO,
was also one of the honorees at the White House ceremony this week.
GenoSpace and MMRF began working last year on an information ecosystem for researchers,
clinicians, and patients living with multiple myeloma that uses data from MMRF's Relating Clinical
Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profiles, or CoMMpass, study.
CoMMpass, which was launched in 2011, is collecting clinical and molecular data from 1,000 newly
diagnosed patients over a minimum of five years and using it to obtain insights into the disease's
progression and treatment response. The study aims to support the discovery of disease
biomarkers, new drug targets, and more personalized treatments approaches. MMRF has worked
with GenoSpace within the last year to create the infrastructure used to store the data and to
provide ready access for visualization and analysis.
Earlier this week, BioInform caught up with Quackenbush, who is also a professor of computational
biology and bioinformatics at the Dana-Farber Cancer Institute and Harvard University's School of
Public Health, to talk about the award and the MMRF project. What follows is an edited version of
the conversation.
Congratulations on winning the award! Did you know you had been nominated?

https://www.genomeweb.com/informatics/qa­genospaces­john­quackenbush­making­data­accessible­research­clinical­and­pati

1/4

1/29/2015

Q&A: GenoSpace's John Quackenbush on Making Data Accessible for Research, Clinical, and Patient Use | GenomeWeb

I had a few people ask me if I was interested in being nominated. One was Kathy from the MMRF,
the other was Brian Athey [the TranSmart Foundation's co-CEO and a professor in the University of
Michigan's computational medicine and bioinformatics department]. I wasn’t sure I would have a
chance but then last week, Kathy and I got a call from the White House. They wanted to ask us a
couple of questions about CoMMpass and what it meant for data to be open. We had a short
conference call on Wednesday of last week. Then we got a call telling us that we were being invited
to the White House and we are going to be recognized for the work we've been doing together.
That’s a pretty impressive accomplishment especially when you consider that you began
partnering with MMRF in the latter half of last year.
On the part of the MMRF, CoMMpass represents an extremely innovative approach to funding and
driving biomedical research. I think from our side what we've managed to put together is an
innovative data portal built on top of a secure repository that really allows you to ask very
sophisticated inquiries of the data.
One of the questions that Michael Stebbins [OSTP's assistant director for biotechnology] from the
White House was asking when he had us on the phone was 'why not just put the data into dbGAP?'
While dbGAP is fantastic as the final repository for data, it doesn’t have the dynamic query
capabilities that really were necessary to help CoMMpass deliver on its promises.
The goal at MMRF was to try and really drive research forward by making the data and information
necessary to interpret it accessible. We felt that the research gateway that we'd developed, and that
we deployed for them, was absolutely what was required to allow their pharma partners, and
ultimately anyone, to explore the data and ask questions that involve understanding both the clinical
and genomic characteristics of the patients enrolled in the study.
How did you end up partnering with MMRF?
In 2011 Mick Corell and I founded GenoSpace. We recognized early on that genomic data was
fundamentally going to be different than most of the other data we'd been dealing with in biomedical
research. Gene expression data isn't identifiable. But GWAS data … and ultimately genome
sequencing data … represents identifiable information. We quickly understood that we would have
to think differently about how we stored and managed that data. We realized that the whole idea of
de-identification no longer made sense because as soon as you have genomic data, it is identifiable.
[So] if genomic data is identifiable, why not forget de-identification altogether. Let's combine clinical
and genomic data in a scalable internet data store that focuses on strong encryption to safeguard
patient confidentiality. We built a large NoSQL database to capture and index all of this data…and
then started building a host of tools that we could snap into place around it.
Then we heard that MMRF was starting CoMMpass. They had gone through a two-year process to
develop specifications for a data resource to support the study and then to identify somebody who
could build it. We heard about an [undisclosed] company that they had essentially settled on. We
approached the MMRF and explained why we didn’t think their solution was going to work. We were
convincing enough that they put us in a 12-week, head-to-head competition with the other vendor.
But six weeks into the project, we had completed nearly everything they asked for and the other
vendor hadn’t really started. So it was pretty clear that we were the group they needed to work with.
Since then, we've really been refining this portal, adding some extremely innovative features, and
https://www.genomeweb.com/informatics/qa­genospaces­john­quackenbush­making­data­accessible­research­clinical­and­pati

2/4

1/29/2015

Q&A: GenoSpace's John Quackenbush on Making Data Accessible for Research, Clinical, and Patient Use | GenomeWeb

making it a tool to drive discovery. The MMRF Research Gateway allows you to combine clinical
and genomic data to ask the kinds of questions you want to ask. We realized that many of the most
important questions people wanted to ask were based on defining and comparing cohorts. Then
[there] are other questions you can ask too about individual genes [and] therapies.
Most importantly, the portal was designed to be very interactive. It’s a discovery engine that’s
designed to take advantage of the genomic data and longitudinal information that’s collected over
the five-year CoMMpass study and to help suggest new ways to explore the study’s unprecedented
information.
So as part of the MMRF partnership, you've developed two so-called gateways to the
CoMMpass data; one for researchers and another for patients. Can you talk a little bit about
what kinds of data and capabilities are available through each one?
The MMRF Researcher Gateway is focused on addressing the needs of research scientists.
CoMMpass is funded through a consortium of pharmaceutical companies. In return for financial
support, they have six months early access to the underlying data allowing them to mine the data
resource and to look for associations between genomic variants and disease. And after six months
they agreed that all this data will be public. The MMRF Researcher Gateway includes tools for
dynamic data analysis and visualization. But we’ve also designed it to facilitate collaborative
analysis. It allows people to build collaborative groups, share results, [and] to track and archive their
research.
Early in our work with MMRF, we started asking how one might go beyond CoMMpass and its first
1,000 patients. We both realized that one way to do this was to create a Community Gateway
designed to allow them to share information with other patients and scientists, but also help match
patients to clinical trials. We’re in a beta release now, but the plan is to open it more broadly in the
fall. The Community Gateway is designed to collect self-reported information, but we could also
upload data from patients' EMRs to capture health data. Ultimately, we hope to connect patients to
trusted providers who can generate genome sequence and provide it.
Beyond the work we’ve done with the MMRF, we’ve also created GenoSpace for Clinical Care that
helps provide detailed, up-to-date, actionable clinical information on mutational profiling data. We
have another partner we hope to announce soon. But here, too, we see opportunities to use this to
provide additional services to patients.
Following up on that last point, is there a plan to use the CoMMpass data to inform clinical
care?
Not directly. It’s a bit of a leap to go from this research data to clinically actionable information. But
ultimately, that is among the goals of CoMMpass, and we believe we have the tools to support it.
One last question on the Open Science Champion award; what does it mean for GenoSpace?
Open data in and of itself isn’t the solution. To make data useful, we need to place it into context,
together with the information necessary to make it useful. And we need to create tools that let
people get access to the data and information in meaningful ways — we need to democratize
access.
At GenoSpace, we’ve built tools that make the data useful, but also to facilitate its broad use. This
https://www.genomeweb.com/informatics/qa­genospaces­john­quackenbush­making­data­accessible­research­clinical­and­pati

3/4

1/29/2015

Q&A: GenoSpace's John Quackenbush on Making Data Accessible for Research, Clinical, and Patient Use | GenomeWeb

award recognizes the progress we’ve made and serves as an additional external validation —
beyond that from our clients — of our strategy.
It is a tremendous honor to be recognized in this way, and it is a testament to the hard work and
dedication the entire GenoSpace team has made.
Filed Under

Informatics

GenoSpace

 Get Weekly Informatics Updates

Related Articles
Jun 25, 2014

Multiple Myeloma Trial Looks at Potential of NGS to Guide Therapy
Jan 07, 2015

MMRF, GNS Healthcare to Collaborate on CoMMpass Study
Feb 12, 2014

In Tackling the VUS Challenge, Are Public Databases the Solution or a Liability
for Labs?
Aug 15, 2014

Thomson Reuters Invests In GenoSpace
Aug 14, 2014

Caris Taps GenoSpace to Support Oncology Service
Sep 23, 2014

GenoSpace Receives $137K Grant to Expand Bioinformatics Portfolio

Privacy Policy.  Copyright © 2015 Genomeweb LLC.  All Rights Reserved.

https://www.genomeweb.com/informatics/qa­genospaces­john­quackenbush­making­data­accessible­research­clinical­and­pati

4/4


Q&A_ GenoSpace's John Quackenbush.pdf - page 1/4
Q&A_ GenoSpace's John Quackenbush.pdf - page 2/4
Q&A_ GenoSpace's John Quackenbush.pdf - page 3/4
Q&A_ GenoSpace's John Quackenbush.pdf - page 4/4

Related documents


PDF Document q a genospace s john quackenbush
PDF Document worksheet questions
PDF Document embi to lead regenstrief institute ibj
PDF Document csp3
PDF Document clinical list america
PDF Document publications presentations media


Related keywords